The global Chemiluminescence Immunoassay Market is estimated to be valued at US$ 7.01 Bn in 2023 and is expected to exhibit a CAGR of 8.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Chemiluminescence immunoassay is a biochemical test used for detection and quantitative measurements of antibodies, antigens, receptors and other biomarkers. It is widely employed in endocrinology, cardiology, infectious diseases, drugs of abuse testing and therapeutic drug monitoring due to accuracy and high sensitivity.

Market key trends:

Rapid diagnostic testing (RDT) has emerged as the fastest growing segment for chemiluminescence immunoassay market. RDT products provide quick diagnosis of various infectious diseases in point-of-care settings such as bedsiders, emergency rooms and clinical laboratories. They help in timely clinical management of patients and prevent unnecessary hospitalizations. Various manufacturers are focusing on developing simple, portable and affordable RDT kits for diseases such as HIV, malaria, dengue, tuberculosis etc. which is fueling the demand for chemiluminescence immunoassay globally.

Segment Analysis

The chemiluminescence immunoassay market is dominated by the Disease Testing subsegment. Disease testing accounts for the largest market share as chemiluminescence immunoassay is widely used for disease screening and diagnosis. It is the most preferred technique for disease testing due to its high sensitivity and specificity.

Key Takeaways

The Global Chemiluminescence Immunoassay Market Size is expected to witness high growth, exhibiting CAGR of 8.0% over the forecast period, due to increasing incidence of chronic and infectious diseases. Rise in geriatric population prone to various diseases and growth in demand for advanced immunoassay techniques are also fueling the market growth.

Regional analysis

The North American region dominates the chemiluminescence immunoassay market owing to rising healthcare expenditure, prevalence of lifestyle diseases, availability of advanced healthcare facilities and presence of leading market players in the region. Asia Pacific is expected to witness the highest growth during the forecast period owing to increasing healthcare expenditures, growing medical tourism industry and rising awareness regarding disease screening and diagnostics in developing countries of the region.

Key players

Key players operating in the chemiluminescence immunoassay market are DiaSorin S.p.A., Abbott Laboratories, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers, Beckman Coulter Inc., F. Hoffmann-La Roche AG, Inova Diagnostics, Inc., Maccura Biotechnology Co., Ltd., Tosoh Corporation, and Ortho Clinical Diagnostic. DiaSorin S.p.A. and Abbott Laboratories dominate the global market owing to their robust product portfolios and strong geographical presence across the world.

Get More Insights:

https://healthcarelatesteditionnews.blogspot.com/2023/12/rapid-diagnostic-testing-is-fastest.html